Endologix Announces Public Offering of Common Stock
A shelf registration statement on Form S-3 relating to the public
offering of the shares of common stock described above was filed with
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
This press release contains “forward-looking statements” within the
meaning of the Private Securities Litigation Reform Act of 1995 and
other federal securities laws. Any statements contained in this press
release that are not statements of historical fact, including but not
limited to statements regarding the proposed offering of common stock
and the intended use of proceeds of the common stock offering, are
forward-looking statements. Words such as “believes,” “anticipates,”
“plans,” “expects,” “will,” “intends,” “potential,” “possible” and
similar expressions are intended to identify forward-looking statements.
These forward-looking statements include our expectations regarding the
proposed offering and the use of proceeds from such offering and are
based on information available to us as of the date they were made.
Forward-looking statements involve risks, uncertainties and other
factors related to our business and the general economic environment,
many of which are beyond our control. These risks, uncertainties and
other factors could cause our actual results to differ materially and
adversely from those projected in forward-looking statements. Although
we believe that the forward-looking statements contained herein are
reasonable, we can give no assurance that our expectations are correct.
All forward-looking statements are expressly qualified in their entirety
by this cautionary statement. For a detailed description of our risks
and uncertainties, you are encouraged to review the Company’s Annual
Report on Form 10-K for the year ended
Vaseem Mahboob, CFO